SciVac Therapeutics Inc.

News Release

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 2, 2016) - SciVac Therapeutics Inc. ("SciVac" or the "Company") (TSX:VAC)(OTCQX:SVACD) today announced, in connection with the previously disclosed proposed business combination between SciVac and VBI Vaccines Inc., an updated biography for SciVac's Chief Financial Officer, James J. Martin.

Mr. Martin's biography is set forth below in its entirety:

James J. Martin, C.P.A. has served as SciVac's Chief Financial Officer since August 2014. Mr. Martin previously served as Chief Financial Officer of SafeStitch Medical, Inc., a medical device company, from January 2011 until October 2013, which was shortly after SafeStitch's acquisition by TransEnterix, Inc. Since January 2011, Mr. Martin has also served as the Chief Financial Officer of Non-Invasive Monitoring Systems, Inc. (OTCBB: NIMU), a company engaged in the development, manufacture and marketing of non-invasive, whole body periodic acceleration therapeutic platforms. Beginning in April 2014, Mr. Martin also served as Chief Financial Officer of Vaporin, Inc. (OTCBB: VAPO), a company engaged in vaporizers and accessories. In March 2015, Vaporin merged with Vapor Corp (NASDAQ: VPCO) and Mr. Martin served as Chief Financial Officer of Vapor Corp. until September 2015. From January 2011 through December 2011, Mr. Martin served as Vice President of Finance of Aero Pharmaceuticals, Inc., referred to as Aero, a privately-held pharmaceutical distributor. From July 2010 until January 2011, Mr. Martin served as the Controller of SafeStitch, NIMS and Aero. From 2008-2010, Mr. Martin served as the Controller of AAR Aircraft Services, Inc., an aerospace and defense company, and from 2005-2008, Mr. Martin served as the Controller of Avborne Heavy Maintenance, Inc., an aviation maintenance repair and overhaul company. In addition to his career in finance and accounting, Mr. Martin served five years in the United States Navy as an Operations Specialist.

About SciVac Therapeutics Inc.

SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. The Company's flagship product, Sci-B-Vac™, is a recombinant 3^rd generation hepatitis B vaccine. The Company also offers contract development and manufacturing services to the life sciences and biotechnology markets.